Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome

Coleman CI, Limone BL

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23631863

DOI
10.1016/j.amjcard.2013.03.036

Indexing Status
Subject indexing assigned by NLM

MeSH
Acute Coronary Syndrome /drug therapy /economics /mortality; Adenosine /analogs & derivatives /economics /therapeutic use; Aged; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs /statistics & numerical data; Drug Therapy, Combination /economics; Drugs, Generic /economics /therapeutic use; Female; Humans; Male; Markov Chains; Myocardial Revascularization /economics; Piperazines /economics /therapeutic use; Platelet Aggregation Inhibitors /economics /therapeutic use; Platelet Function Tests /economics; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12 /blood /drug effects; Survival Rate; Thiophenes /economics /therapeutic use; Ticlopidine /analogs & derivatives /economics /therapeutic use

AccessionNumber
22013018354

Date bibliographic record published
17/06/2013